At an 11-Year Low with a 4.9% Dividend Yield, Is This Value Stock a No-Brainer Buy for Passive Income in 2026?

Clorox, which fell 37.9% in 2025 versus a 16.4% gain for the S&P 500, is guiding fiscal 2026 organic sales to decline 5–9% (with a cited ~7.5bp ERP transition impact) after abnormally large retailer shipments at the end of FY2025 tied to an ERP rollout. Management is completing a multiyear turnaround—upgrading ERP and exiting noncore geographies and businesses—which the company says will restore efficiency; net long-term debt is under $3bn with a D/E of ~0.2. The stock yields ~4.9% after a $1.24 quarterly dividend (48th straight annual increase), making it a contrarian, income-oriented pick for investors with a 3–5 year horizon despite weak near-term results.

Analysis

Market structure: CLX's 38% drawdown and 4.9% yield repositions it as a value/income destination; income-seeking retail and yield ETFs (high-dividend baskets) are short-term winners while discretionary and private-label producers (store brands) are the main competitive threats. ERP-driven channel stuffing -> retailer destocking signals a near-term negative demand impulse (organic sales guided -5% to -9% FY26) but also implies a higher probability of catch-up orders once inventories normalize (12–18 months). Cross-asset: elevated equity implied vol for CLX creates opportunities in options; modest spread widening in staples credit is possible but limited given D/E~0.2.

Risk assessment: Tail risks include prolonged ERP failure/cost overruns, a renewed material cyber event, or a consumer recession shaving >5% off staples volumes — any would threaten the dividend if free cash flow drops below dividends for two consecutive quarters. Time horizons: immediate (days) = earnings/guide headlines and vol spikes; short-term (1–6 months) = retailer restocking and sequential organic sales; long-term (12–36 months) = ERP run-rate benefits and margin recovery. Hidden dependencies: retailer inventory policies, private-label pricing, and FX from past divestitures can change realized growth faster than guidance.

Trade implications: Direct: build a size-weighted long in CLX (conviction income trade) while using option structures to cap downside; rotate marginal dollars from broad staples ETFs into select names like CLX and PG depending on risk appetite. Options: sell 3-month 10% OTM covered calls to collect yield if long, or buy 9–15 month call spreads (buy LEAP ~10–20% ITM, sell ~30–40% OTM) for asymmetric upside; protective 3–6 month puts (15% OTM) if downside protection is required.

Contrarian angles: Consensus understates ERP upside — historical analogs (major ERP rollouts) often create 6–18 month haircuts followed by 15–40% operational leverage as working capital and SG&A normalize. The market may be overpricing permanent demand loss; if sequential organic sales improve by >100 bps over two quarters or management hits ERP milestones (cost saves >$100–200m run-rate) the re-rating could be rapid. Conversely, if dividend payout ratio rises above 80% or FCF falls below dividend for two consecutive quarters, the contrarian case breaks.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in CLX (NYSE: CLX) in tranches: 50% immediately, +25% on a further -10% pullback, +25% on -20%. Target horizon 12–36 months; hard stop-loss at -25% from entry or immediate exit if dividend cut or two consecutive quarters where FCF < dividend.
• Hedge/option strategy: if taking equity long, sell 3-month covered calls 10% OTM to harvest premium (rollable) and simultaneously buy 9–15 month call spreads (buy a LEAP ~10% ITM, sell strike ~30–40% OTM) to retain upside with defined risk; alternative protective hedge = buy 3–6 month puts 15% OTM sized at 25–50% of position cost.
• Relative-value pair: Go long CLX (2% weight) and short PG (1% weight) as a mean-reversion play over 6–18 months — rationale: CLX has higher yield and larger implied upside from rerating while PG offers defensive offset; tighten size if CLX underperforms after two consecutive quarters.
• Milestone-based add: Add remaining conviction capital (+1–2% weight) if CLX posts two consecutive quarters with sequential organic sales improvement >=100 bps AND management cites ERP run-rate cost savings >=$100M. Do not add if payout ratio >80% or FCF < dividend for two sequential quarters.